Food and Drug Administration, HHS.
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
Fax written comments on the collection of information by December 19, 2007.
To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, FAX: 202-395-6974, or e-mailed to firstname.lastname@example.org. All comments should be identified with the OMB control number 0910-0540. Also include the FDA docket number found in brackets in the heading of this document.Start Further Info
FOR FURTHER INFORMATION CONTACT:
Denver Presley Jr., Office of the Chief Information Officer (HFA-250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1472.End Further Info End Preamble Start Supplemental Information
In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.
Animal Drug User Fees and Fee Waivers and Reductions-21 CFR Part 740 (OMB Control Number 0910-0540)—Extension
Enacted on November 18, 2003, the Animal Drug User Fee Act (ADUFA) (Public Law 108-130), amended the Federal Food, Drug, and Cosmetic Act and requires FDA to assess and collect user fees for certain applications, products, establishments, and sponsors. It also requires the agency to grant a waiver from, or a reduction of, those fees in certain circumstances. Thus, to implement this statutory provision of ADUFA, FDA developed a guidance entitled “Guidance for Industry: Animal Drug User Fees and Fee Waivers and Reductions.” This document provides guidance on the types of fees FDA is authorized to collect under ADUFA, and how to request waivers and reductions from FDA's animal drug user fees. Further, this guidance also describes the types of fees and fee waivers and reductions, what information FDA recommends be submitted in support of a request for a fee waiver or reduction, how to submit such a request, and FDA's process for reviewing requests. Requests for waivers or reductions may be submitted by a person paying any of the animal drug user fees assessed—application fees, product fees, establishment fees, or sponsor fees.
In the Federal Register of June 14, 2007 (72 FR 32851), FDA published a 60-day notice requesting public comment on the information collection provisions. No comments were received.
Respondents to this collection of information are new animal drug sponsors.
FDA estimates the burden for this collection of information as follows:Start Printed Page 65038
|21 CFR Section||No. of Respondents||Annual Frequency per Response||Total Annual Responses||Hours per Response||Total Hours|
|740(d)(1)(A) Significant barrier to innovation||5||1 time for each application||5||2||10|
|740(d)(1)(B) Fees exceed cost||1||do.||1||2||2|
|740(d)(1)(C) Free choice feeds||5||do.||5||2||10|
|740(d)(1)(D) Minor use or minor species||10||do.||10||2||20|
|740(d)(1)(E) Small business||2||do.||2||2||4|
|Request for reconsideration of a decision||5||do.||5||2||10|
|Request for review—(user fee appeal officer)||2||do.||2||2||4|
|1 There are no capital costs or operating and maintenance costs associated with this collection of information.|
Based on FDA's database system, there are an estimated 250 sponsors of products subject to ADUFA. However, not all sponsors will have any submissions in a given year and some may have multiple submissions. The total number of waiver requests is based on the number of submission types received by FDA in fiscal year 2003. FDA's Center for Veterinary Medicine estimates 30 waiver requests that include the following: 5 significant barriers to innovation, 1 fee exceed cost, 5 free choice feeds, 10 minor use or minor species, 2 small business waiver requests, 5 requests for reconsideration of a decision, and 2 requests for user fee appeal officer. The estimated hours per response are based on past FDA experience with the various waiver requests in FDA's Center for Drug Evaluation and Research. The hours per response are based on the average of these estimates.Start Signature
Dated: November 13, 2007.
Assistant Commissioner for Policy.
[FR Doc. E7-22495 Filed 11-16-07; 8:45 am]
BILLING CODE 4160-01-S